Drug and gene delivery devices market seen reaching $1.01 billion by 2030

The drug and gene delivery devices market is projected to grow from $0.73 billion in 2026 to $1.01 billion by 2030, according to The Business Research Company. Growth is being driven by gene therapy adoption, smart delivery technologies, and wider use of nanoparticle and viral vector platforms.

Why it matters: - Drug and gene delivery devices are becoming a bigger part of personalized medicine and gene therapy. - The market is expected to nearly double from 2025 to 2030, signaling stronger demand for targeted treatment tools. - Growth in delivery technology could improve precision, controlled release and outcomes for patients with complex conditions.

What happened: - The Business Research Company published a market report on the global drug and gene delivery devices sector. - The market is projected to rise from $0.67 billion in 2025 to $0.73 billion in 2026. - The report forecasts the market will reach $1.01 billion by 2030. - The 2025-2026 period implies 8.9% CAGR growth. - The 2026-2030 period implies 8.6% CAGR growth. - North America held the largest market share in 2025.

The details: - Drug and gene delivery devices administer pharmaceuticals or genetic material directly into the body. - These devices are designed to improve accuracy, controlled release and delivery to specific cells or tissues. - The report links recent growth to limited availability of advanced delivery technologies, dependence on traditional administration methods, early-stage gene therapy development, a growing biologic drug pipeline and higher investment in collaborative research. - The forecast points to progress in viral and non-viral vector systems. - The forecast also highlights broader use of nanomedicine and lipid nanoparticle technologies. - Digital monitoring and smart delivery solutions are expected to gain more traction. - The report flags targeted therapies, nanoparticle-based delivery, expanded viral vector use, injectable and non-invasive delivery approaches, and individualized treatment as key trends. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report offers market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - A free sample is available here. - The full report is available here.

Between the lines: - Gene therapy adoption appears to be a major demand driver because delivery systems are essential for getting genetic material to the right place. - The report’s emphasis on smart delivery, nanoparticles and vector systems suggests the market is shifting from basic administration toward more precise platform technologies. - North America’s lead likely reflects stronger regulatory infrastructure and investment capacity. - In January 2025, the American Society of Gene & Cell Therapy reported an 83% increase in pre-registration gene therapy programs in Q4 2024 compared with Q3 2024. - That jump was the largest in more than a year and points to a pipeline that could keep supporting device demand.

What's next: - The market is expected to keep expanding through 2030 as gene therapy and personalized medicine broaden. - More regulatory approvals for new delivery platforms could accelerate adoption. - Wider use of digital monitoring and non-invasive delivery approaches may reshape product development. - The company’s report package includes updated forecasts and visuals for tracking segment and regional opportunities.